logo
  

Huntington Ingalls Industries To Buy UniversalPegasus; Terms UnDisclosed

Huntington Ingalls Industries (HII) announced Friday that it agreed to acquire UniversalPegasus International Holdings or UPI, a provider of engineering and project management services to the domestic and international energy markets.

The transaction is subject to Hart-Scott-Rodino review and customary closing conditions and is expected to close in June. The value of the transaction is not being disclosed. UPI is a privately held company headquartered in Houston, Texas.

UPI has approximately 1,500 employees and has provided a broad range of engineering and project management services to the energy industry for over 50 years. They safely and reliably deliver project management, engineering, design, survey, inspection and construction management to customers in the domestic and international marketplaces.

After the acquisition closes, UPI will report to Chris Kastner, corporate vice president and general manager, corporate development.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT